77 related articles for article (PubMed ID: 10101145)
41. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
42. Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses.
Beránková K; Szkutová M; Balíková M
Forensic Sci Int; 2007 Aug; 170(2-3):94-9. PubMed ID: 17629428
[TBL] [Abstract][Full Text] [Related]
43. The pharmacokinetics of a novel anti-tumor agent, beta-elemene, in Sprague-Dawley rats.
Wang K; Li Z; Chen Y; Su C
Biopharm Drug Dispos; 2005 Oct; 26(7):301-7. PubMed ID: 16041842
[TBL] [Abstract][Full Text] [Related]
44. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats.
Gandhi V; Chen W; Ayres M; Rhie JK; Madden TL; Newman RA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):85-94. PubMed ID: 12172971
[TBL] [Abstract][Full Text] [Related]
45. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
46. Studies on disease-modifying antirheumatic drugs. III. Bone resorption inhibitory effects of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl) quinoline-3-carboxylate (TAK-603) and related compounds.
Baba A; Oda T; Taketomi S; Notoya K; Nishimura A; Makino H; Sohda T
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):369-74. PubMed ID: 10212387
[TBL] [Abstract][Full Text] [Related]
47. Investigation of the unique metabolic fate of ethyl (6R)-6- [N- (2-chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in rats and dogs using two types of 14C-labeled compounds having different labeled positions.
Jinno F; Kakehi M; Takeuchi T; Tagawa Y; Kondo T; Asahi S
Arzneimittelforschung; 2011; 61(8):458-71. PubMed ID: 21950150
[TBL] [Abstract][Full Text] [Related]
48. Kinetic analysis of glycyrrhetic acid, an active metabolite of glycyrrhizin, in rats: role of enterohepatic circulation.
Kawakami J; Yamamura Y; Santa T; Kotaki H; Uchino K; Sawada Y; Iga T
J Pharm Sci; 1993 Mar; 82(3):301-5. PubMed ID: 8450426
[TBL] [Abstract][Full Text] [Related]
49. Formation of a disulfide protein conjugate of the SH-group-containing metabolite (M-I) of esonarimod (KE-298) and its elimination in rats.
Hasegawa M; Omi N; Endo H; Yoshida H; Higuchi S
J Pharm Pharmacol; 2002 Apr; 54(4):493-8. PubMed ID: 11999126
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of methylergometrine in the rat: evidence for enterohepatic recirculation by a linked-rat model.
Bredberg U; Paalzow L
Pharm Res; 1990 Jan; 7(1):14-20. PubMed ID: 2300530
[TBL] [Abstract][Full Text] [Related]
51. The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S; Benet LZ
Drug Metab Dispos; 2019 Sep; 47(9):1004-1012. PubMed ID: 31201213
[TBL] [Abstract][Full Text] [Related]
52. Disposition of the Highly Fat Distributed Compound 1-(4-Methoxyphenyl)-4-(2,2,4,6,7-Pentamethyl -2,3-Dihydro-1-Benzofuran-5-yl)Piperazine (TAK-357) in Rats and Dogs.
Goto A; Moriya Y; Mandai T; Wakabayashi T; Tsukamoto T; Tagawa Y; Kondo T; Asahi S
Drug Res (Stuttg); 2017 Jan; 67(1):38-45. PubMed ID: 27728931
[TBL] [Abstract][Full Text] [Related]
53. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites.
Schwartz DE; Eckert G; Hartmann D; Weber B; Richard-Lenoble D; Ekue JM; Gentilini M
Chemotherapy; 1982; 28(1):70-84. PubMed ID: 6976886
[TBL] [Abstract][Full Text] [Related]
54. The effect of elevated α
Ebihara T; Shimizu H; Yamamoto M; Higuchi T; Jinno F; Tagawa Y
Xenobiotica; 2019 May; 49(5):584-590. PubMed ID: 29790816
[TBL] [Abstract][Full Text] [Related]
55. Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b:5,4-c']dipyridine derivatives and their anti-inflammatory effect.
Baba A; Mori A; Yasuma T; Unno S; Makino H; Sohda T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):993-9. PubMed ID: 10434400
[TBL] [Abstract][Full Text] [Related]
56. Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats.
Yoshida H; Kohno Y; Endo H; Hasegawa M; Yamaguchi J; Tomisawa K; Suwa T
Biol Pharm Bull; 1996 Mar; 19(3):424-9. PubMed ID: 8924913
[TBL] [Abstract][Full Text] [Related]
57. [Studies on the metabolic effect of growth promotors, using nitrovin as a model. 2. Studies on the enterohepatic circulation of 14C-labeled nitrovin in the rat].
Struck S; Günther KD; Hillemeir H; ter Meulen U
Z Tierphysiol Tierernahr Futtermittelkd; 1980; 43(4-5):191-6. PubMed ID: 7405409
[No Abstract] [Full Text] [Related]
58. Pharmacokinetics of indoprofen (4-[1,3-dihydro-1-oxo-2H-isoindol-2-yl)-alpha-methylbenzene acetic acid) in the rat: influence of exteriorization of the bile duct and explanation of selective toxicity in the rat.
Kershaw RA; Staubus A; Sharp DE; Bianchine J; Gerber N
Proc West Pharmacol Soc; 1983; 26():397-401. PubMed ID: 6889370
[No Abstract] [Full Text] [Related]
59. Plasma pharmacokinetic and metabolism of [
Mairinger S; Filip T; Sauberer M; Flunkert S; Wanek T; Stanek J; Furtner S; Hutter-Paier B; Okamura N; Kuntner C
Nucl Med Biol; 2020; 84-85():28-32. PubMed ID: 31981857
[TBL] [Abstract][Full Text] [Related]
60. Divided-dose kinetics of mefloquine in man.
Franssen G; Rouveix B; Lebras J; Bauchet J; Verdier F; Michon C; Bricaire F
Br J Clin Pharmacol; 1989 Aug; 28(2):179-84. PubMed ID: 2789071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
